Strong Satisfaction Levels with Adalimumab Biosimilar Seen Among Initiators, Switchers with IBD
This new analysis on IBD patients initiating biologic therapy with the biosimilar ABP 501 indicates that the drug’s lower cost and efficacy may lead to greater use.
Source: hcplive.com